Pharma Patent Cliffby readouts.io
Generic and biosimilar makers · US

Who profits from the cliff

The companies lined up to sell copies of the drugs on this tracker, from the FDA's approval lists and the brand owners' own filings. 54 companies across 30 drugs.

CompanyDrugs targeted2025 sales of those brandsDrugs
Sandoz 10 $71.5B Stelara, Prolia, Xgeva, Farxiga, Pomalyst, Lynparza, Keytruda, Otezla, Enbrel, Rinvoq
Samsung Bioepis 9 $79.0B Stelara, Prolia, Xgeva, Keytruda, Enbrel, Taltz, Dupixent, Tremfya, Entyvio
Cipla 9 $71.1B Farxiga, Pomalyst, Lynparza, Keytruda, Otezla, Descovy, Cabometyx, Calquence, Biktarvy
Celltrion 8 $74.0B Stelara, Prolia, Xgeva, Keytruda, Darzalex, Cosentyx, Taltz, Tremfya
Teva 7 $38.2B Stelara, Prolia, Farxiga, Pomalyst, Ocrevus, Cabometyx, Entyvio
Zydus 6 $72.7B Entresto, Farxiga, Lynparza, Keytruda, Otezla, Ozempic
Dr. Reddy's 6 $53.9B Entresto, Pomalyst, Jakafi, Darzalex, Cosentyx, Ozempic
Alvotech 6 $31.3B Stelara, Taltz, Tremfya, Kesimpta, Imfinzi, Entyvio
Biocon 6 $30.8B Entresto, Stelara, Prolia, Xgeva, Farxiga, Cabometyx
MSN 6 $27.6B Entresto, Farxiga, Pomalyst, Jakafi, Cabometyx, Calquence
Lupin 5 $39.2B Entresto, Farxiga, Xtandi, Descovy, Biktarvy
Amgen 4 $56.3B Stelara, Keytruda, Opdivo, Ocrevus
Henlius 4 $52.5B Prolia, Xgeva, Keytruda, Darzalex
Sun Pharma 4 $33.4B Pomalyst, Jakafi, Ozempic, Rinvoq
Apotex 4 $27.9B Pomalyst, Jakafi, Descovy, Ozempic
Hetero 4 $21.5B Entresto, Pomalyst, Descovy, Rinvoq
Alkem 4 $21.5B Entresto, Farxiga, Otezla, Jakafi
Hikma 4 $15.7B Stelara, Prolia, Xgeva, Jakafi
Viatris (Mylan) 3 $36.5B Pomalyst, Eliquis, Ozempic
Aurobindo 3 $24.4B Entresto, Farxiga, Rinvoq
Alembic 3 $19.2B Entresto, Farxiga, Jakafi
Macleods 3 $18.9B Entresto, Farxiga, Descovy
Accord 3 $12.6B Stelara, Prolia, Xgeva
Fresenius Kabi 3 $12.6B Stelara, Prolia, Xgeva
Alvogen 2 $24.2B Ozempic, Imbruvica
Micro Labs 2 $22.8B Farxiga, Eliquis
Laurus Labs 2 $22.0B Entresto, Biktarvy
Polpharma 2 $13.6B Ocrevus, Tremfya
Bio-Thera 2 $12.8B Stelara, Cosentyx
Torrent 2 $10.0B Entresto, Otezla
Natco 2 $8.2B Lynparza, Imbruvica
Amneal 2 $6.5B Prolia, Xgeva
Eugia 2 $5.8B Pomalyst, Jakafi
BioNTech 1 $31.7B Keytruda
Formycon 1 $31.7B Keytruda
mAbxience 1 $31.7B Keytruda
Qilu 1 $31.7B Keytruda
Rio Biopharmaceuticals 1 $19.3B Ozempic
Chong Kun Dang 1 $17.8B Dupixent
CSPC 1 $17.8B Dupixent
CinnaGen 1 $8.4B Ocrevus
Aizant 1 $8.4B Farxiga
Ajanta 1 $8.4B Farxiga
Inventia 1 $8.4B Farxiga
Intas 1 $8.3B Rinvoq
Crystal Pharmaceutical 1 $7.7B Entresto
Novugen 1 $7.7B Entresto
Somerset Therapeutics 1 $7.7B Entresto
Umedica 1 $7.7B Entresto
Ascent 1 $6.0B Xtandi
Granules 1 $3.1B Jakafi
Breckenridge 1 $2.7B Pomalyst
Azurity 1 $2.1B Cabometyx
Handa 1 $2.1B Cabometyx

A company counts as targeting a drug if it holds an FDA approval for a copy, has filed for one, has settled or lost a patent case over one, or has a disclosed development program. Brand sales are what the brands earned in 2025, not what any maker will capture; several makers usually share a market.